Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of “Buy” by Analysts

Keros Therapeutics, Inc. (NASDAQ:KROS) has earned a consensus rating of “Buy” from the seven analysts that are covering the stock, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy rating. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $92.17.

Several equities analysts have weighed in on KROS shares. Oppenheimer began coverage on shares of Keros Therapeutics in a report on Tuesday, June 25th. They set an “outperform” rating and a $102.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 target price on shares of Keros Therapeutics in a report on Tuesday, June 18th. Finally, Truist Financial reiterated a “buy” rating and issued a $100.00 price target on shares of Keros Therapeutics in a research note on Tuesday, June 18th.

Insider Buying and Selling at Keros Therapeutics

In other news, Director Carl L. Gordon sold 250,000 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the completion of the transaction, the director now owns 119,522 shares in the company, valued at $5,260,163.22. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 22.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Keros Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Keros Therapeutics by 1.9% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,149 shares of the company’s stock worth $870,000 after acquiring an additional 251 shares in the last quarter. Ameritas Investment Partners Inc. increased its position in Keros Therapeutics by 14.5% in the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock worth $169,000 after purchasing an additional 324 shares during the last quarter. Principal Financial Group Inc. raised its stake in Keros Therapeutics by 8.8% during the first quarter. Principal Financial Group Inc. now owns 7,063 shares of the company’s stock valued at $468,000 after purchasing an additional 574 shares in the last quarter. Arizona State Retirement System lifted its position in Keros Therapeutics by 16.3% during the second quarter. Arizona State Retirement System now owns 8,077 shares of the company’s stock valued at $369,000 after purchasing an additional 1,130 shares during the last quarter. Finally, American International Group Inc. grew its stake in shares of Keros Therapeutics by 13.1% in the 1st quarter. American International Group Inc. now owns 12,653 shares of the company’s stock worth $838,000 after buying an additional 1,465 shares in the last quarter. 71.56% of the stock is owned by institutional investors.

Keros Therapeutics Stock Performance

NASDAQ KROS opened at $47.34 on Thursday. The business’s fifty day moving average is $46.81 and its 200 day moving average is $54.62. Keros Therapeutics has a fifty-two week low of $27.02 and a fifty-two week high of $73.00. The company has a market capitalization of $1.71 billion, a PE ratio of -9.19 and a beta of 1.23.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.02). The firm had revenue of $0.04 million during the quarter. During the same period in the prior year, the company earned ($1.27) EPS. On average, sell-side analysts forecast that Keros Therapeutics will post -4.8 EPS for the current year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.